‘Because we generate and use antibodies in our own laboratories, we are in a position to better address your needs’

The experience of Medimabs’ founders who constitute the firm’s management team combines:

Miguel Madanes Founding Investor, President and Board Member, has been Director of the board of YPF S.A., the oldest oil company in Argentina, since 1991.He was Chairman of the Board (1997-1998), and was named Executive Vice-President in 1995. Prior to this position, he was CEO of Fate S.A. and Aluar 1976-1993, a leading Argentine industrial group comprising production of primary aluminum, manufacture of aluminum products and manufacture and sales of tires.He has also served as member of the Privatization Committee of the Economy Ministry (1989-1990). He holds a degree in Industrial Engineering from the University of Buenos Aires.

Dr. A. Claudio Cuello MD. DSc. FRS(C), Founder, Board Member,  is a well established scientist, listed as a “Highly Cited Neuroscientist” by the Institute of Scientific Information, USA. He has published more than 300 papers and edited several books. Dr Cuello has received numerous Awards and Academic distinctions. He has been made a Fellow of the Royal Society of Canada. He has served in the Universities of Buenos Aires, UCSF (Univ. of California, San Francisco), Cambridge (England) and Oxford (England). He presently holds the position of Professor and Charles E. Frosst Chair in Pharmacology at McGill University. He also holds an Adjunct Professorship at The Scripps Institute, La Jolla, Ca, USA. His vast knowledge of antibodies arises from his extensive collaboration with Cesar Milstein (Nobel Laureate and creator of Monoclonal Antibodies). He has generated numerous monoclonal antibodies which are presently widely commercialized.

Sarita Benchimol BSc. MSc, Chief Operating Officer, has been working in the research field for over 30 years both as a laboratory assistant and as an administrator. She has experience in many areas of research, particularly in hypertension, infectious diseases and cancer. She has been involved in the management of research groups for over 20 years. She possesses wide experience in biotechnology.  She has acquired extensive knowledge in the business/scientific network. She has participated in the launching and development of several university start up companies, such as Phagetech Inc. and Novothera Biotechnologies. She has had active involvement in numerous partnerships between university and industry.

Dr.Phil Gold CC, OQ, MD, PhD, FRS(C), FRCP(C), MACP, Board Member, is the Douglas G. Cameron Professor of Medicine, and Professor of Physiology and Oncology, at McGill University. He has served as Chairman of the Department of Medicine at McGill and Physician-in-Chief at the Montreal General Hospital. He is presently the Executive Director of the Clinical Research Centre of the McGill University Health Centre. Dr. Gold’s early research in immunology and his work on antibodies led to the discovery and definition of the Carcinoembryonic Antigen (CEA), the blood test most frequently used in the diagnosis and management of patients with cancer.